Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. - Wikidata - wikimedia - TriplyDB

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

http://www.wikidata.org/entity/Q33946929

about

Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma Emerging molecularly targeted therapies in castration refractory prostate cancer Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy New drugs in prostate cancer Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer c-Met as a Target for Personalized Therapy Growth factor and signaling pathways and their relevance to prostate cancer therapeutics Anti-angiogenesis in prostate cancer: knocked down but not out Cabozantinib for progressive metastatic medullary thyroid cancer: a review Met in urological cancers Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer Recent progress in pharmaceutical therapies for castration-resistant prostate cancer Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Novel non-AR therapeutic targets in castrate resistant prostate cancer Can oncology recapitulate paleontology? Lessons from species extinctions Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Bone metastases: Causes, consequences and therapeutic opportunities The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells Bone-targeting agents in prostate cancer.Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.Plasma membrane proteomics of human breast cancer cell lines identifies potential targets for breast cancer diagnosis and treatment.Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth.Molecular pathways and targets in prostate cancer The role of epithelial plasticity in prostate cancer dissemination and treatment resistance Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib

P2860

Q21245750-D2D6F7D3-34C3-4E1F-B35E-7DE3D856DA2B Q21284745-AD1FFD6C-9425-4C4B-877E-68E4F4009DE4 Q26741450-56140E93-2600-4CA2-82AB-CDA8A66345B9 Q26745948-06DFD29B-B5E8-4A40-92F8-68745B236EB1 Q26748872-E7BC187B-7C01-45B6-AFFA-4576583C330C Q26752785-320B5531-013F-4C02-8150-4ABE1003966F Q26775483-D71BE1AB-6513-4CE3-B249-F705D6A63F03 Q26827975-21A909FB-CB41-483B-9DBC-38235B62B370 Q26851183-DBF1094C-2352-4EE7-AB44-DD34A9370F46 Q26851709-E9FD581B-CFD2-42FF-B220-7DA797DAC446 Q26864988-02F71F15-CEB3-4E38-BF1A-FE593E578770 Q26866135-792E79F6-2886-40CF-9225-5B662B72C778 Q27010542-2BF89647-6CBE-41E3-B065-709B8C45F2CF Q27022567-3D697E67-87A7-4D13-994D-533F2509C3E9 Q27024775-0A31DB67-E5EB-427F-B2E1-3F4358930A30 Q28074834-9599AF57-CEC3-4F72-86A5-9B8BF38D35E8 Q28082793-FFEB707B-6689-4837-80A2-78184F6D7197 Q28383663-D24B6E47-2912-4328-ACF0-69D3C9078146 Q28607703-F0F972EC-3478-4D78-BAD8-799BCA20A9F9 Q30250303-8FDD3BA3-3161-417A-AF4F-114761A0A656 Q30409623-34ED271D-5C13-446C-B946-408FF4AE597D Q33424270-71744B53-42BB-459C-968F-6894E1E6D3C7 Q33429467-169F63A7-0635-46E7-8F6A-5B685D811CC6 Q33441170-26B453A6-00A4-4EBA-A51A-8CC2BEB854E9 Q33633424-3C301B87-BDF5-4E74-B9F5-E4F465C3C34B Q33697331-995118D9-9980-4E18-A8A6-34639F9C7C72 Q33769429-FE17ADB1-3FD0-4FE2-9A35-31A5EDFD4852 Q33769437-1AC66A38-931C-4167-9421-FC3F4A6A10B9 Q33788066-23091340-23F0-4570-86F9-1A91A00ABC92 Q33823715-AC6CDB41-59DD-48AF-B6D8-698DEB0F28D9 Q33864723-5BA39555-44BD-483E-9149-CF4F531680F1 Q33880064-2B724938-8C17-457B-B234-FD482641AFBE Q33910532-34A1A0AF-946C-4D75-A9D8-91089B7AEA10 Q34309227-9AC20BF0-729F-4CFD-80AB-7C8374A85B2D Q34330748-52EBA177-9F4C-479C-AB63-E590338F4AB8 Q34353130-285737E0-CA59-48DE-AC52-F7B3A25139BB Q34365632-5E241F8E-82FD-45F5-BA29-55E96DADD2BF Q34505037-7CC216E8-29D0-41C6-9F9A-0D3E00498148 Q34537725-98818FAD-34B5-4247-A55F-0C8418D8CB9F Q34541663-CFEA6E18-D806-4FA2-B474-8CE3871BE8FC

P2860

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

http://www.wikidata.org/entity/Q33946929

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Cabozantinib in patients with ...... domized discontinuation trial.

@ast

Cabozantinib in patients with ...... domized discontinuation trial.

@en

type

label

Cabozantinib in patients with ...... domized discontinuation trial.

@ast

Cabozantinib in patients with ...... domized discontinuation trial.

@en

prefLabel

Cabozantinib in patients with ...... domized discontinuation trial.

@ast

Cabozantinib in patients with ...... domized discontinuation trial.

@en

P1433

Q33946929-482719B9-C697-4F40-AEBE-B43DCFA609BE

P1476

Q33946929-8BE5423F-8E5D-4B78-BD52-1A01B24FF2E0

P2093

Q33946929-06B38C3E-5371-4C43-83B0-22F5978A76CB

Q33946929-1373A0AF-B782-469C-AC95-8A6521CAA80B

Q33946929-16BD7E7B-3A67-4A84-B4EE-B0CDDCC42DED

Q33946929-1A8A5ACF-5366-410F-84AA-D8EE82177EDE

Q33946929-1DB8252F-4C3A-4738-BAC0-8F1AD9308B0C

Q33946929-1E17C06C-BBCF-4698-B4EB-5F0E10D51266

Q33946929-5EB4A12F-035D-46B4-9EFC-9C635921CD0F

Q33946929-6CEC45B6-6216-43A6-B602-C152DB6C6AFB

Q33946929-8A887449-0650-492C-842F-5803EFFC0296

Q33946929-A0976FF2-D01E-4C6E-9FC6-4BDC0D7E6C0D

P2860

Q33946929-031A268E-A56E-440C-BFA6-0E5F34F3BD6C

Q33946929-0A141114-0A16-4CE8-B486-99BC52331F44

Q33946929-0BC6E26A-E0EA-4B23-96F9-2B0BB4141C6D

Q33946929-12CB597C-2538-4A7B-AF1D-843229737512

Q33946929-395635A7-89C6-4948-B656-C2A74B892FE1

Q33946929-467613A1-BE6A-437B-B352-E957C356ABE6

Q33946929-5779F004-48C2-4F45-A812-E53CA28E8468

Q33946929-5A1447E5-43AC-41E4-8EB4-F4ED51CF829A

Q33946929-6FB36DC2-B27C-4B9D-A0C3-94831C0A1331

Q33946929-71A11D99-A97A-401B-9827-B3B75206E844

P304

Q33946929-982602E6-2096-4217-B4D5-48A5CE858685

P31

Q33946929-C2601B88-CA9E-4142-98D8-F1EF167E07C8

P356

Q33946929-4513D7FA-BF76-411A-900B-7B6B37605D67

P407

Q33946929-2FD30761-DCCC-41AA-843E-AC017856FA9D

P433

Q33946929-FF9522CA-6A88-419C-AC6E-892A298E14BB

P478

Q33946929-5720A193-C011-42B2-82BD-A6B997B9255E

P50

Q33946929-C42C9005-E238-47C7-BFAA-AD6DA107A695

P577

Q33946929-426CED31-6E8E-41DB-9FE4-BE348E7AF03E

P5875

Q33946929-A937CDA4-4593-449A-88E4-6A89764F9F93

P698

Q33946929-50B1DAB3-B7D9-44F3-83FD-69098DFEB195

P921

Q33946929-10A73469-120E-48DA-A328-DEDA44742579

Q33946929-24029E89-C667-415C-80B2-BA79A2F5466D

P932

Q33946929-32E9B89D-AAE9-409B-9066-3211C5379032

P356

JCO.2012.45.0494

P1433

Journal of Clinical Oncology

P1476

Cabozantinib in patients with ...... domized discontinuation trial.

@en

P2093

Aaron L Weitzman

http://www.w3.org/2001/XMLSchema#string

Alexander I Spira

http://www.w3.org/2001/XMLSchema#string

Andrea L Harzstark

http://www.w3.org/2001/XMLSchema#string

Avishay Sella

http://www.w3.org/2001/XMLSchema#string

Aymen A Elfiky

http://www.w3.org/2001/XMLSchema#string

Chia-Chi Lin

http://www.w3.org/2001/XMLSchema#string

Christian Scheffold

http://www.w3.org/2001/XMLSchema#string

Christopher Logothetis

http://www.w3.org/2001/XMLSchema#string

Christopher Sweeney

http://www.w3.org/2001/XMLSchema#string

David C Smith

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

High expression of the Met receptor in prostate cancer metastasis to bone.

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

MET and VEGF: synergistic targets in castration-resistant prostate cancer

Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair.

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

P304

412-419

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.45.0494

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Patrick Schöffski

P577

2012-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233738485

http://www.w3.org/2001/XMLSchema#string

P698

23169517

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4110249

http://www.w3.org/2001/XMLSchema#string